{"title":"Targeting RAS in gastrointestinal malignancies.","authors":"Oluseyi Abidoye, Celine Hoyek, Tanios Bekaii-Saab","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Kirsten rat sarcoma virus (KRAS) is one of the prevalent oncogenic drivers in gastrointestinal (GI) cancers, including pancreatic ductal adenocarcinoma and colorectal cancer. The KRAS protein is a GTPase that activates several signaling pathways involved in cancer survival. Although KRAS mutations have long been considered difficult to target, recent advances have led to the development of small-molecule inhibitors targeting the mutations, particularly KRAS G12C. These inhibitors are showing promise in GI cancers. This review explores the molecular biology of KRAS mutations, their prevalence in GI malignancies, the current therapeutic approaches targeting KRAS, ongoing clinical trials, the challenges associated with resistance, and future directions for KRAS-targeted therapies in GI cancers.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 2","pages":"111-122"},"PeriodicalIF":1.1000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Advances in Hematology & Oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Kirsten rat sarcoma virus (KRAS) is one of the prevalent oncogenic drivers in gastrointestinal (GI) cancers, including pancreatic ductal adenocarcinoma and colorectal cancer. The KRAS protein is a GTPase that activates several signaling pathways involved in cancer survival. Although KRAS mutations have long been considered difficult to target, recent advances have led to the development of small-molecule inhibitors targeting the mutations, particularly KRAS G12C. These inhibitors are showing promise in GI cancers. This review explores the molecular biology of KRAS mutations, their prevalence in GI malignancies, the current therapeutic approaches targeting KRAS, ongoing clinical trials, the challenges associated with resistance, and future directions for KRAS-targeted therapies in GI cancers.
期刊介绍：
Clinical Advances in Hematology & Oncology (CAH&O) is a monthly peer-reviewed journal reaching more than 27,000 hematology and oncology clinicians. CAH&O provides editorial content encompassing a wide array of topics relevant and useful to the fields of oncology and hematology, both separately and together. Content is directed by the strong input of today’s top thought leaders in hematology & oncology, including feature-length review articles, monthly columns consisting of engaging interviews with experts on current issues in solid tumor oncology, hematologic malignancies, hematologic disorders, drug development, and clinical case studies with expert commentary. CAH&O also publishes industry-supported meeting highlights, clinical roundtable monographs, and clinical review supplements.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
